These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 10070221

  • 1. [Effects of bezafibrate in the diet of hypertensive patients with dyslipidemia and hyperfibrinogenemia].
    Vázquez-Chávez C, Salinas-Orozco S, Gómez-Díaz RA, Rosso-Juárez MM, Moreno-Vázquez K, Nissen-Torres T, Argüero-Sánchez R.
    Rev Invest Clin; 1998; 50(6):491-6. PubMed ID: 10070221
    [Abstract] [Full Text] [Related]

  • 2. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
    Cortellaro M, Cofrancesco E, Boschetti C, Cortellaro F, Mancini M, Mariani M, Paoletti R.
    Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
    [Abstract] [Full Text] [Related]

  • 3. [Bezafibrate in the treatment of familial combined hyperlipidemia and its effect on certain parameters of lipid metabolism, particularly fibrinogen].
    Urbánek R, Coufal Z.
    Vnitr Lek; 1998 May; 44(5):259-62. PubMed ID: 9820067
    [Abstract] [Full Text] [Related]

  • 4. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

  • 5. Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response.
    Cenarro A, Artieda M, Gonzalvo C, Meriño-Ibarra E, Arístegui R, Gañán A, Díaz C, Sol JM, Pocoví M, Civeira F, ATOMIX Study Group.
    Am Heart J; 2005 Dec; 150(6):1154-62. PubMed ID: 16338252
    [Abstract] [Full Text] [Related]

  • 6. Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients.
    Taniguchi A, Fukushima M, Sakai M, Tokuyama K, Nagata I, Fukunaga A, Kishimoto H, Doi K, Yamashita Y, Matsuura T, Kitatani N, Okumura T, Nagasaka S, Nakaishi S, Nakai Y.
    Metabolism; 2001 Apr; 50(4):477-80. PubMed ID: 11288046
    [Abstract] [Full Text] [Related]

  • 7. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study.
    Goldbourt U, Brunner D, Behar S, Reicher-Reiss H.
    Eur Heart J; 1998 Jul; 19 Suppl H():H42-7. PubMed ID: 9717065
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the effects of bezafibrate and acipimox on the lipid pattern and plasma fibrinogen in hyperlipidaemic type 2 (non-insulin-dependent) diabetic patients.
    Niort G, Cassader M, Gambino R, Pagano G.
    Diabete Metab; 1992 Jul; 18(3):221-8. PubMed ID: 1397477
    [Abstract] [Full Text] [Related]

  • 9. The effect of a slow release formulation of bezafibrate on lipids, glucose homeostasis, platelets and fibrinogen in type II diabetics: a pilot study.
    Mathur S, Barradas MA, Mikhailidis DP, Dandona P.
    Diabetes Res; 1990 Jul; 14(3):133-8. PubMed ID: 2132185
    [Abstract] [Full Text] [Related]

  • 10. Plasma levels of E-selectin in normolipemic and hyperlipemic arteriopathic patients after vasoactive and lipid-lowering treatment.
    Ferlito S, Gallina M, Mugno F, Bisicchia A, Di Salvo MM.
    Minerva Cardioangiol; 2000 Mar; 48(3):47-52. PubMed ID: 10838833
    [Abstract] [Full Text] [Related]

  • 11. High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study.
    Arcavi L, Behar S, Caspi A, Reshef N, Boyko V, Knobler H.
    Am Heart J; 2004 Feb; 147(2):239-45. PubMed ID: 14760320
    [Abstract] [Full Text] [Related]

  • 12. Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome.
    Jastrzebska M, Torbus-Lisiecka B, Pieczul-Mróz J, Chelstowski K, Kopciewicz J, Naruszewicz M.
    Int J Clin Pharmacol Res; 1999 Feb; 19(1):19-25. PubMed ID: 10450539
    [Abstract] [Full Text] [Related]

  • 13. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives.
    Haenni A, Lithell H.
    J Hypertens Suppl; 1999 Aug; 17(3):S29-35. PubMed ID: 10489096
    [Abstract] [Full Text] [Related]

  • 14. [Comparison of the efficacy of pantethine, acipimox, and bezafibrate on plasma lipids and index of cardiovascular risk in diabetics with dyslipidemia].
    Tonutti L, Taboga C, Noacco C.
    Minerva Med; 1991 Oct; 82(10):657-63. PubMed ID: 1745376
    [Abstract] [Full Text] [Related]

  • 15. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC, Ciccariello L, Perrone F, Stoico V, Gussoni G, Scotti A, Muggeo M.
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of bezafibrate on lipids, lipoproteins, apolipoproteins and platelet aggregation in hypertriglyceridemic patients.
    Waysbort J, Schwartz S, Brunner D.
    Arzneimittelforschung; 1994 Nov; 44(11):1217-22. PubMed ID: 7893284
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.